Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11882MR)

This product GTTS-WQ11882MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11882MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7911MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ11716MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ13800MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ7810MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ9595MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ11517MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ11099MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ11394MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW